Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
UTC Therapeutics Inc.
Beijing Friendship Hospital
NGM Biopharmaceuticals, Inc
University Hospital, Ghent
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Universitair Ziekenhuis Brussel
Immix Biopharma, Inc.
Kineta Inc.
Namida Lab
Shanghai Yunying Medical Technology
MiRXES Pte Ltd
Impact Therapeutics, Inc.
Wuhan Ammunition Life-tech Co., Ltd
Blue Note Therapeutics
Main Line Health
Assistance Publique - Hôpitaux de Paris
Weprom
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
SpeciCare
University Hospital Tuebingen
Shenzhen BinDeBio Ltd.
Tel-Aviv Sourasky Medical Center
University of Magdeburg
Instituto do Cancer do Estado de São Paulo
Critical Outcome Technologies Inc.
Placon Therapeutics
Xuanwu Hospital, Beijing
SPGO Research Mannheim GmbH
Chinese PLA General Hospital
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Poniard Pharmaceuticals
Hillel Yaffe Medical Center
Novacea
Julius-Maximilians University
Aronex Pharmaceuticals